Circulating tumor DNA as prognostic markers of relapsed breast cancer: a systematic review and meta-analysis.

ABSTRACT:

Objective

Circulating tumor DNA (ctDNA) is increasingly being used as a potential prognosis biomarker in patients of breast cancer. This review aims to assess the clinical value of ctDNA in outcome prediction in breast cancer patients throughout the whole treatment cycle.

Methods

PubMed, Web of Science, Embase, Cochrane Library, Scopus, and clinical trials.gov were searched from January 2016 to May 2022. Conference abstracts published in last three years were also included. The following search terms were used: ctDNA OR circulating tumor DNA AND breast cancer OR breast carcinoma. Only studies written in English languages were included. The following pre-specified criteria should be met for inclusion: (1) observational studies (prospective or retrospective), randomized contro

SUBMITTER: Guo N 

PROVIDER: S-EPMC11256521 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature